Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 14/20 | 0.56 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | DRD1 | P21728 | 6/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774649 | 0.90 | DRD3 (0.56) | DRD3DRD2DRD1DRD4 | |
| SCHEMBL6779841 | 0.90 | DRD3 (0.56) | DRD3DRD2DRD1DRD4KDM4E | |
| SCHEMBL6774117 | 0.90 | DRD3 (0.60) | DRD3DRD2DRD1DRD4 | |
| SCHEMBL6776218 | 0.89 | DRD3 (0.58) | DRD3DRD2DRD1DRD4KDM4E | |
| SCHEMBL6779377 | 0.87 | DRD3 (0.55) | DRD3DRD2DRD1DRD4KDM4E | |
| SCHEMBL6780044 | 0.80 | DRD3 (0.51) | DRD3DRD2DRD1DRD4KDM4E | |
| SCHEMBL6773782 | 0.80 | KDM4E (0.44) | DRD3DRD2DRD4KDM4ELMNA | |
| SCHEMBL6780665 | 0.79 | KDM4E (0.48) | DRD3DRD2DRD4KDM4ELMNA | |
| SCHEMBL6774177 | 0.78 | DRD3 (0.58) | DRD3DRD2DRD1DRD4 | |
| SCHEMBL6773398 | 0.78 | DRD3 (0.53) | DRD3DRD2DRD1DRD4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713634-B2 | SEROTONIN RECEPTOR ANTAGONIST | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20030166926-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2003-09-04 | — | — | US | disclosed |
| US-6489473-B2 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION | SUNTORY LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020072515-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0807632-B1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LTD (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6258805-B1 | TREATMENT OF BRAIN DISORDERS AND HYPERTENSION | SUNTORY LIMITED (JP) | 2001-07-10 | — | — | US | disclosed |
| EP-0807632-A1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072515-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | DRD3 165/4885DRD2 34/4885DRD1 141/4885 |
| US-20030166926-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | DRD3 173/4885DRD2 34/4885DRD1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.